| 101 |
22444679 | Radioiodinated sunitinib as a potential radiotracer for imaging angiogenesis-radiosynthesis and first radiopharmacological evaluation of 5-[125I]Iodo-sunitinib. | 2012 Apr 15 |
4 |
| 102 |
22572725 | Antiangiogenic approaches for the treatment of advanced synovial sarcomas. | 2012 Jul |
2 |
| 103 |
22592949 | Relevance of angiogenesis in neuroendocrine tumors. | 2012 Jun |
1 |
| 104 |
22607009 | Sunitinib malate for the treatment of renal cell carcinoma. | 2012 Jun |
2 |
| 105 |
22819259 | Blockade of NFκB activity by Sunitinib increases cell death in Bortezomib-treated endometrial carcinoma cells. | 2012 Oct |
1 |
| 106 |
22904678 | The effect of bevacizumab on human malignant melanoma cells with functional VEGF/VEGFR2 autocrine and intracrine signaling loops. | 2012 Jul |
1 |
| 107 |
22967802 | Preclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer. | 2012 Sep 11 |
2 |
| 108 |
23102636 | Strategic combination therapy overcomes tyrosine kinase coactivation in adrenocortical carcinoma. | 2012 Dec |
1 |
| 109 |
24451769 | Systemic therapeutic approaches to advanced thyroid cancers. | 2012 |
2 |
| 110 |
25806151 | Angiogenesis in cancer: Anti-VEGF escape mechanisms. | 2012 Mar |
1 |
| 111 |
20872043 | Phase II study of sunitinib malate in patients with recurrent high-grade glioma. | 2011 Jul |
1 |
| 112 |
21242589 | Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect. | 2011 Jul |
1 |
| 113 |
21325074 | Identification of soluble candidate biomarkers of therapeutic response to sunitinib in medullary thyroid carcinoma in preclinical models. | 2011 Apr 1 |
1 |
| 114 |
21447721 | Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies. | 2011 Apr 1 |
2 |
| 115 |
21463120 | Sunitinib in relapsed or refractory diffuse large B-cell lymphoma: a clinical and pharmacodynamic phase II multicenter study of the NCIC Clinical Trials Group. | 2011 May |
2 |
| 116 |
21693010 | Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. | 2011 Jun 21 |
4 |
| 117 |
21744079 | Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma. | 2011 Dec |
2 |
| 118 |
21980525 | VEGFR2 translocates to the nucleus to regulate its own transcription. | 2011 |
2 |
| 119 |
22038997 | Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. | 2011 Dec 15 |
2 |
| 120 |
22130231 | Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. | 2011 |
2 |
| 121 |
19444655 | Olecranon bursitis in patients treated with sunitinib for renal cell carcinoma. | 2010 Jun |
2 |
| 122 |
19649772 | Phase II study of sunitinib malate in head and neck squamous cell carcinoma. | 2010 Oct |
1 |
| 123 |
20039326 | Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways. | 2010 Sep 1 |
1 |
| 124 |
20072832 | Sunitinib. | 2010 |
2 |
| 125 |
20103629 | Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. | 2010 Feb 1 |
3 |
| 126 |
20103668 | Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. | 2010 Feb 1 |
1 |
| 127 |
20204363 | Spontaneous bilateral pneumothorax in metastatic renal cell carcinoma on sunitinib therapy. | 2010 Jul |
1 |
| 128 |
20215359 | Everolimus (RAD001) in the treatment of advanced renal cell carcinoma: a review. | 2010 |
3 |
| 129 |
20351323 | Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. | 2010 May 1 |
3 |
| 130 |
20599738 | Sunitinib deregulates tumor adaptation to hypoxia by inhibiting HIF-1alpha synthesis in HT-29 colon cancer cells. | 2010 Jul 23 |
1 |
| 131 |
20686367 | SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth via targeting both tumor vasculature and breast cancer cells. | 2010 Oct 1 |
1 |
| 132 |
20686603 | The 4q12 amplicon in malignant peripheral nerve sheath tumors: consequences on gene expression and implications for sunitinib treatment. | 2010 Jul 29 |
1 |
| 133 |
20721275 | Bevacizumab demonstrates prolonged disease stabilization in patients with heavily pretreated metastatic renal cell carcinoma: a case series and review of the literature. | 2010 |
2 |
| 134 |
21187479 | The effects of anti-VEGFR and anti-EGFR agents on glioma cell migration through implication of growth factors with integrins. | 2010 Dec |
3 |
| 135 |
19284623 | Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers. | 2009 Mar 12 |
1 |
| 136 |
19318229 | Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. | 2009 Jun |
2 |
| 137 |
19453268 | Sunitinib in solid tumors. | 2009 Jun |
1 |
| 138 |
19689244 | Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. | 2009 Jun |
1 |
| 139 |
19726307 | [Establishment of homogeneous time-resolved fluorescence immunoassay for high throughput screening of protein tyrosine kinase inhibitors]. | 2009 Aug |
3 |
| 140 |
19754358 | Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. | 2009 Sep |
3 |
| 141 |
19767240 | Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. | 2009 Oct |
4 |
| 142 |
19811659 | Chromophobe renal cell cancer--review of the literature and potential methods of treating metastatic disease. | 2009 Oct 7 |
1 |
| 143 |
19844230 | Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. | 2009 Nov 17 |
1 |
| 144 |
19911111 | Sunitinib paves the way for targeted therapies in neuroendocrine tumors. | 2009 Dec |
1 |
| 145 |
20877672 | Significance of Tyrosine Kinase Inhibitors in the Treatment of Metastatic Breast Cancer. | 2009 |
2 |
| 146 |
17505827 | A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period. | 2008 Mar |
1 |
| 147 |
17962201 | Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. | 2008 Feb |
1 |
| 148 |
18082353 | Sunitinib in the management of gastrointestinal stromal tumours (GISTs). | 2008 Aug |
4 |
| 149 |
18347007 | Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. | 2008 Apr 10 |
2 |
| 150 |
18474019 | New anti-angiogenic targeted therapy in advanced renal cell carcinoma (RCC): current status and future prospects. | 2008 May |
2 |